6:45 AM — 6:35 PM

Exhibits Open

6:45 AM — 8:00 AM

Continental Breakfast Provided

Welcome

8:00 AM — 9:45 AM

General Session I: Radiation Therapy in the Management of Early-to-Intermediate-Risk Prostate Cancer*

Chairs: Jeff Michalski, MD – Washington University School of Medicine; Jason A. Efstathiou, MD– Massachusetts General Hospital

• Role of Dose Escalation and Supplemental Androgen Deprivation
  Daniel Krauss, MD – William Beaumont Medical School
   
• Hypofractionation: Is Less Better? 
  W. Robert Lee, MD – Duke University School of Medicine
   
• Panel Discussion: Post-Prostatectomy Radiation Therapy: When and For Whom?
  Moderator: Richard K. Valicenti, MD - University of California, Davis
  Christopher Parker, MD – The Royal Marsden and Institute for Cancer Research
  Edouard J. Trabulsi, MD – Thomas Jefferson University
  Andrew Stephenson, MD – Cleveland Clinic 

9:45 AM — 10:15 AM

Break

10:15 AM — 11:45 AM

General Session II: Castration-Resistant Prostate Cancer -- Treatment Sequencing and Implementation*

Chairs: Kim N. Chi, MD – British Columbia Cancer Agency; Christopher Sweeney, MBBS – Dana-Farber Cancer Institute

• Approved Agents and Related Trials 
  Gary R. MacVicar, MD – Northwestern University
   
• Rational Sequencing
  Philip W. Kantoff, MD – Dana-Farber Cancer Institute
   
• Novel Targets, Agents, and Trials
  Evan Y. Yu, MD – University of Washington Seattle Cancer Care Alliance
   
• Abstract #LBA1: Overall survival results from the phase III AFFIRM trial for MDV3100, an androgen receptor signaling inhibitor (ARSI), in patients with advanced prostate cancer.
  Presenting Author: Howard I. Scher
  
  
• Case Study and Panel Discussion
  Gary R. MacVicar, MD – Northwestern University
  Philip W. Kantoff, MD – Dana-Farber Cancer Institute
  Evan Y. Yu, MD – University of Washington Seattle Cancer Care Alliance

11:45 AM — 1:15 PM

General Poster Session A: Prostate Cancer

(with complimentary boxed lunch)

1:15 PM — 3:05 PM

Oral Abstract Session: Prostate Cancer^

Chairs: Rob Reiter, MD – University of California, Los Angeles; Peter Carroll, MD – University of California, San Francisco
 

• Abstract #2: Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort—Results from the Canary/EDRN Prostate Active Surveillance Study. 
  Presenting Author: Daniel W. Lin 
   
• Abstract #3: Comparative effectiveness of intensity modulated radiation therapy (IMRT), proton therapy (PT), and conformal radiation therapy (CRT) in the treatment of localized prostate cancer.
  Presenting Author: Nathan Christopher Sheets 
   
• Abstract #4: Long-term toxicity and associated cost of initial treatment and subsequent toxicity-related intervention for patients treated with prostatectomy, external beam radiotherapy, or brachytherapy: A SEER/Medicare database study.
  Presenting Author: Jay P. Ciezki
  
  
• Discussion (Abstracts #3-4)
  Paul L. Nguyen, MD - Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School
   
• Abstract #5: Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. 
  Presenting Author: David D. Orsted
   
• Abstract #6: Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. 
  Presenting Author: Matthew R. Smith
   
• Abstract #7: Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
  Presenting Author: Eric A. Klein
   
• Abstract #8: Overall survival benefit and safety profile of radium-223 chloride (Alpharadin), a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.
  Presenting Author: Chris Parker

3:05 PM — 3:35 PM

Break

3:35 PM — 5:05 PM

General Session III: Translational Science: Prostate Cancer

Chairs: Christopher P. Evans, MD – University of California, Davis; Martin E. Gleave, MD – Prostate Center at Vancouver General Hospital
 

• The Bone Microenvironment: Does It Matter?
  Evan T. Keller, DVM, PhD – University of Michigan 
   
• Introduction to Androgen-Receptor Splice Variants and Their Significance Elahe A. Mostaghel, MD, PhD – Fred Hutchinson Cancer Research Center 
   
• The Androgen Receptor: New Points of Attack
  Marianne Sadar, PhD – British Columbia Cancer Agency
   
• Androgen Receptor Adaptation and Resistance: Can We Overcome It?
  Jack Schalken, PhD - Radboud University Nijmegen
   
• Redundant Molecular Pathways in Prostate Cancer 
  Brett S. Carver, MD – Memorial Sloan-Kettering Cancer Center

5:05 PM — 6:35 PM

General Poster Session B: Prostate Cancer

(with complimentary wine and cheese reception)

5:20 PM — 6:35 PM

Fellows Poster Walk: Prostate Cancer (ticketed)

(Attendance limited to Fellows, Residents, and Junior Faculty)

Joel B. Nelson, MD - University of Pittsburgh

Glenn Liu, MD - University of Wisconsin
 

6:45 AM — 6:45 PM

Exhibits Open

6:45 AM — 7:55 AM

Continental Breakfast Provided

7:00 AM — 7:45 AM

Best of Journals: Prostate cancer

• Urologist: David F. Jarrard, MD – University of Wisconsin School of Medicine and Public Health
• Radiation Oncologist: Justin Bekelman, MD – University of Pennsylvania
• Medical Oncologist: Ulka N. Vaishampayan, MD – Karmanos Cancer Institute

8:00 AM — 9:30 AM

General Session IV: Urothelial Carcinomas*

Chairs: Sandy Srinivas, MD – Stanford Medical Center; Bernard H. Bochner, MD – Memorial Sloan-Kettering Cancer Center
 

• Geriatric Oncology: How Age-Related Physiologic Changes and Comorbidities Affect Chemotherapy Choices, Toxicity, and Response
  Arti Hurria, MD – City of Hope
   
• Upper Tract Disease: 2011 European Association of Urology Guidelines
  Joan Palou, MD - Fundació Puigvert, Barcelona
   
• Translating Level I Evidence into Clinical Practice: Opportunities and Threats
  Brent K. Hollenbeck, MD, MS – University of Michigan
   
• Challenging Cases in Upper Tract Disease: Case Presentation and Panel Discussion
  Medical Oncologist: Daniel P. Petrylak, MD – Columbia Presbyterian Medical
                                Center
  Urologist:            Surena F. Matin, MD – University of Texas M.D. Anderson
                                Cancer Center
  Pathologist:        Donna E. Hansel, MD, PhD – The Cleveland Clinic
  Radiologist:        Benjamin M. Yeh, MD – University of California, San Francisco

9:30 AM — 10:00 AM

Break

10:45 AM — 12:15 PM

General Session V: Translational Science Session: Urothelial Carcinomas

Chairs: Dan Theodorescu, MD, PhD – University of Colorado; Ganesh Raj, MD, PhD – UT Southwestern Medical Center

• Abstract #260: Association of single-nucleotide polymorphisms in BCL2L1 and TACC3 with response to bacillus Calmette-Guérin intravesical therapy in non-muscle-invasive bladder cancer. 
  Presenting Author: Shaheen Alanee
  
  
• Introduction
  Ganesh Raj, MD, PhD - University of Texas Southwestern Medical Center
   
• How Will Gene-Expression Data Inform Risk Stratification and Treatment Selection?
  Dan Theodorescu, MD, PhD - University of Colorado
   
• Using Multiplex Techniques to Discover New Markers and Targets in Urothelial Carcinoma: An Update
  Jonathan E. Rosenberg, MD - Dana-Farber Cancer Institute/Harvard Cancer Center
   
• Estrogen Receptors and Selective Estrogen Receptor Modulators in Bladder Cancer
  Carolyn L. Smith, PhD - Baylor College of Medicine
   
• Heritable Factors in Bladder Cancer Risk, Prognosis, and Treatment Response
  Lambertus A. Kiemeney, MD - Nijmegen Medical Centre

12:15 PM — 1:45 PM

General Poster Session C: Prostate Cancer

12:30 PM — 1:45 PM

Fellows, Residents, and Junior Faculty Networking Luncheon (Ticketed)

Chairs: Brian J. Davis, MD, PhD - Mayo Clinic and Foundation; Eric J. Small, MD – University of California, San Francisco
 

1:45 PM — 3:15 PM

Oral Abstract Session: Penile, Urethral, Urothelial, and Testicular Cancers^

Bruce J. Roth, MD – Washington University School of Medicine; Seth P. Lerner, MD – Baylor College of Medicine

• Abstract #324: Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields.
  Presenting Author: Jonathan J. Paly
   
• Discussion (Abstract #324)
  Lois Travis, MD - University of Rochester 
   
• Abstract #261: Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.
  Presenting Author: Arlene O. Siefker-Radtke
   
• Abstract #262: A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.
  Presenting Author: Brian C. Baumann 
   
• Abstract #263: Risk-adapted screening in bladder cancer using the open-access Internet-based questionnaire Risk Check bladder cancer: First evaluation by the health services research foundation IQUO, Germany. Presenting Author: Gerson Luedecke
  
  
• Abstract #264: Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.
  Presenting Author: Raymond H. Mak
   
• Abstract #265: Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).
  Presenting Author: Petros Grivas

3:15 PM — 3:45 PM

Break

3:45 PM — 5:15 PM

General Session VI: Testicular Cancer: Maximizing Cure While Minimizing the burden of therapy for germ cell tumors

Chairs: Timothy D. Gilligan, MD – Cleveland Clinic; Karim Fizazi, MD, PhD – Institut Gustave Roussy

• The Development and Role of Adjuvant Therapy in Stage I Testis Cancer 
  Thomas Powles, MD - St. Bartholomews Hospital
   
• Long-term Risks of Adjuvant Therapy and the Role of Surveillance in Stage I Testis Cancer
  Sophie D. Fossa, MD – The Norwegian Radium Hospital
  
  
• Postchemotherapy Management: When Is Surgery Warranted?
  Axel Heidenreich, MD – RWTH Aachen University
   
• Postchemotherapy Relapse: Do We Need a Randomized Trial of Standard versus High-Dose Chemotherapy?
  Darren R. Feldman, MD – Memorial Sloan-Kettering Cancer Center
   
• Abstract #323: Most relapses occurring in metastatic germ-cell tumors are at least partially explained by the  lack of compliance to international guidelines: A study from the Institut Gustave Roussy.
  Presenting Author: Constance Thibault

5:15 PM — 6:45 PM

General Poster Session D: Penile, Urethral, Urothelial, and Testicular Cancers

(with complimentary wine and cheese reception)  
 

5:45 PM — 6:45 PM

Fellows Poster Walk: Penile, Urethral, Urothelial, and Testicular Cancers (ticketed)

(Attendance limited to Fellows, Residents, and Junior Faculty)

Toni Choueiri, MD - Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical Center

Ian Davis, MD - Ludwig Institute for Cancer Research
 

6:45 AM — 8:00 AM

General Poster Session E: Renal Cancer

(with complimentary continental breakfast)

7:00 AM — 7:45 AM

Best of Journals session: Renal Cancer

• Translational Perspective: Elizabeth Plimack, MD - Fox Chase Cancer Center
• Urologist: Gennady Bratslavsky, MD - National Cancer Institute
• Medical Oncologist: Naomi B. Haas, MD - Abramson Cancer Center

7:55 AM — 8:00 AM

Welcome

8:00 AM — 9:30 AM

General Session VII: Competing Risks and Treatment Trade-Offs: Kidney Cancer in the Vulnerable patient

Chairs: Robert Uzzo, MD – Fox Chase Cancer Center; Alexander S. Parker, PhD – Mayo Clinic

• Comorbidity Scores and Quantifying Competing Risks in the Vulnerable Patient
  Brian Egleston, MD - Fox Chase Cancer Center
   
• Panel Discussion: Cancer vs Functional Risks
  Moderator: Robert Uzzo, MD – Fox Chase Cancer Center
  
  Urologist: "Kidney Cancer Kills"
  Maxwell V. Meng, MD – University of California, San Francisco 
  
  Nephrologist: "Dialysis Kills"
  Mitchell H. Rosner, MD – University of Virginia 
  
  Medical Actuary: "How Actuaries Make the Call"
  Susan Pantely, FSA, MAAA - Milliman and Associates
   
• When to Treat: Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Renal Cell Carcinoma
  Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Institute
   
• Optimal Sequencing in Systemic Therapy
  Robert A. Figlin, MD – Cedars Sinai Medical Center

9:30 AM — 10:00 AM

Break

10:00 AM — 11:30 PM

Oral Abstract Session C: Renal Cancer^

Chairs: Paul Russo, MD – Memorial Sloan-Kettering Cancer Center; Joaquim Bellmunt, MD – Hospital del Mar

• Abstract #349: Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
  Presenting Author: Christopher J. Richards
   
• Abstract #350: Preoperative antiangiogenic treatment of RCC patients inhibits angiogenesis in the primary tumor: Rapid angiogenesis onset after discontinuation of sunitinib.
  Presenting Author: Axel Bex
  
  
• Abstract #351: Chronic kidney disease and the risk of incident renal and urothelial cancer in a population-based cohort of 1.2 million adults.
  Presenting Author: William T. Lowrance
   
• Discussion (Abstracts #349-351)
  Thomas E. Hutson, DO, PharmD – Baylor Sammons Cancer Center
   
• Abstract #352: Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET).
  Presenting Author: Angela Q. Qu
  
  
• Abstract #353: A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.
  Presenting Author: Daniel Y. C. Heng
   
• Abstract #354: Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.
  Presenting Author: Brian I. Rini
   
• Abstract #355^: A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.
  Presenting Author: Toni K. Choueiri
   
• Discussion (Abstracts #352-355^)
  Daniel Cho, MD – Beth Israel Deaconess Medical Center

11:50 AM — 1:05 PM

General Poster Session E: Renal Cancer

(with complimentary boxed lunch)

1:05 PM — 2:35 PM

General Session VIII: Translational Science Sessions: Renal Cancer

Chairs: Cora N. Sternberg, MD – San Camillo Forlanini Hospital; Hyung L. Kim, MD – Cedars-Sinai Medical Center

• Immunotherapy for Kidney Cancer: A Renaissance on the Horizon?
  David F. McDermott, MD – Beth Israel Deaconess Medical Center
   
• Epigenetic and Genetic Profiling in Kidney Cancer
  Paul Cairns, PhD – Fox Chase Cancer Center
   
• Tomorrow’s Targets
  Michael Atkins, MD – Beth Israel Deaconess Medical Center
   
• Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards?
  Ana M. Molina, MD – Memorial Sloan-Kettering Cancer Institute
   
• Abstract #348: Improved overall survival (OS) observed in a phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).
  Presenting Author: Robert A. Figlin
  

— Indicates Ticketed Session (information on registering for ticketed sessions)
* -- Indicates use of the Audience Response System (ARS)
^ -- Indicates use of the electronic Q&A system (eQ&A)